BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29891024)

  • 1. Inhibitory Effects of Baicalein Derived from Japanese Traditional Herbal Medicine on SN-38 Glucuronidation.
    Satoh T; Igarashi A; Tanno M; Yamada K; Takahashi-Suzuki N; Watanabe K
    J Pharm Pharm Sci; 2018; 21(1):195-206. PubMed ID: 29891024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of UDP-glucuronosyltransferase (UGT)-mediated glycyrrhetinic acid 3-O-glucuronidation by polyphenols and triterpenoids.
    Koyama M; Shirahata T; Hirashima R; Kobayashi Y; Itoh T; Fujiwara R
    Drug Metab Pharmacokinet; 2017 Aug; 32(4):218-223. PubMed ID: 28754329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9.
    Xiao L; Zhu L; Li W; Li C; Cao Y; Ge G; Sun X
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):424-428. PubMed ID: 29076612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
    Shiraga T; Yajima K; Suzuki K; Suzuki K; Hashimoto T; Iwatsubo T; Miyashita A; Usui T
    Drug Metab Dispos; 2012 Feb; 40(2):276-82. PubMed ID: 22031623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of baicalin to baicalein significantly strengthens the inhibition potential towards UDP-glucuronosyltransferases (UGTs) isoforms.
    Teng Y; Nian H; Zhao H; Chen P; Wang G
    Pharmazie; 2013 Sep; 68(9):763-7. PubMed ID: 24147345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity.
    Katoh M; Yoshioka Y; Nakagawa N; Yokoi T
    Drug Metab Pharmacokinet; 2009; 24(3):226-34. PubMed ID: 19571434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
    Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
    Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral pharmacokinetics of baicalin, wogonoside, oroxylin A 7-O-β-d-glucuronide and their aglycones from an aqueous extract of Scutellariae Radix in the rat.
    Cai Y; Li S; Li T; Zhou R; Wai AT; Yan R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1026():124-133. PubMed ID: 26809374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
    Liu Y; Ramírez J; House L; Ratain MJ
    Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.
    Oleson L; Court MH
    J Pharm Pharmacol; 2008 Sep; 60(9):1175-82. PubMed ID: 18718121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate.
    Yokoi T; Narita M; Nagai E; Hagiwara H; Aburada M; Kamataki T
    Jpn J Cancer Res; 1995 Oct; 86(10):985-9. PubMed ID: 7493919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin.
    Qi C; Fu J; Zhao H; Xing H; Dong D; Wu B
    Xenobiotica; 2019 Mar; 49(3):276-283. PubMed ID: 29436891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
    Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
    Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan].
    Tanaka Y; Katoh M; Fujioka M; Onishi K; Sakakibara Y; Hasegawa T; Nadai M
    Yakugaku Zasshi; 2013; 133(4):463-71. PubMed ID: 23328499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.
    Watanabe Y; Nakajima M; Yokoi T
    Drug Metab Dispos; 2002 Dec; 30(12):1462-9. PubMed ID: 12433820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases.
    Yu L; Lu S; Lin Y; Zeng S
    Biochem Pharmacol; 2007 Jun; 73(11):1842-51. PubMed ID: 17359941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
    Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
    Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
    Ramírez J; Mirkov S; House LK; Ratain MJ
    Drug Metab Dispos; 2015 Jul; 43(7):928-35. PubMed ID: 25870101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
    Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
    Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.